No significant differences in the MDA, SOD and GSH-Px concentrations were noted between groups C and D
Lifestyle modification remains the fundamental basis of MASLD treatment, and pharmacological treatment is increasingly recognized as fundamental support, mainly in patients with biopsy-confirmed MASH, significant fibrosis ( F2), or cardiometabolic comorbidity 8
1 A 2011 comparative effectiveness review showed that metformin, second-generation sulfonylureas, thiazolidinediones, and repaglinide (Prandin) lowered A1C levels by about 1% when used as monotherapy and that combination therapies showed an additive effect on A1C levels
[9] [10] The incidence of thyroid neoplasms remained extremely low and comparable between treatment and control groups
I increased my water intake, aiming for 80-100 oz daily